Back to Results
First PageMeta Content
Medicine / Alcohols / Amines / Overactive bladder / Incontinence / Oxybutynin / Darifenacin / Urinary incontinence / Fesoterodine / Chemistry / Muscarinic antagonists / Organic chemistry


CONTROL Trial (CL2008-13) and Safety Review - FDA perspective
Add to Reading List

Open Document

File Size: 784,92 KB

Share Result on Facebook

Company

Merck / /

Event

FDA Phase / /

IndustryTerm

receptor agonist product / anti-muscarinic products / /

MedicalCondition

overactive bladder / Diabetes Bladder cancer Urinary tract infection Pregnancy Prostate disease / urgency urinary incontinence / urge urinary incontinence / /

Organization

FDA / Reproductive and Urologic Products Nonprescription Drugs Advisory Committee / Division of Reproductive / /

Person

Donald McNellis / /

Position

Director / Division of Nonprescription Clinical Evaluation November / /

Product

Oxytrol / Tolterodine / Rx / Oxybutynin tablets / Oxytrol® / Transdermal Oxybutynin Patch / /

SocialTag